These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 39204336)
21. Detection of natural compounds by virtual screening, molecular docking and dynamics studies and evaluation of their effects on tau level Uzunhisarcıklı E; Çelik İ; Yerer MB J Biomol Struct Dyn; 2024; 42(1):384-392. PubMed ID: 36946204 [TBL] [Abstract][Full Text] [Related]
22. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors. Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963 [TBL] [Abstract][Full Text] [Related]
23. Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer's Disease: An Liu S; Dang M; Lei Y; Ahmad SS; Khalid M; Kamal MA; Chen L Curr Pharm Des; 2020; 26(37):4808-4814. PubMed ID: 32264807 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466 [TBL] [Abstract][Full Text] [Related]
25. Exploring the therapeutic potential of prolinamides as multi-targeted agents for Alzheimer's disease treatment: molecular docking and molecular dynamic simulation studies. Olalekan SO; Obakachi VA; Badeji AA; Akinsipo Oyelaja OB; Familoni O; Asekun OT; Oladipo SD; Osinubi AD In Silico Pharmacol; 2024; 12(2):80. PubMed ID: 39224128 [TBL] [Abstract][Full Text] [Related]
26. In Silico Discovery and Predictive Modeling of Novel Acetylcholinesterase (AChE) Inhibitors for Alzheimer's Treatment. Suha HN; Hossain MS; Rahman S; Alodhayb A; Hossain MM; Kawsar SMA; Poirier R; Uddin KM Med Chem; 2024 May; ():. PubMed ID: 38803179 [TBL] [Abstract][Full Text] [Related]
27. Investigation of Patil N; Chandel V; Rana A; Jain M; Kaushik P Plants (Basel); 2023 Jan; 12(3):. PubMed ID: 36771595 [No Abstract] [Full Text] [Related]
28. In Silico Approaches to Developing Novel Glycogen Synthase Kinase 3β (GSK-3β). Goyal S; Singh M; Thirumal D; Sharma P; Mujwar S; Mishra KK; Singh TG; Singh R; Singh V; Singh T; Ahmad SF Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893156 [TBL] [Abstract][Full Text] [Related]
29. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. Mazumder MK; Choudhury S Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161 [TBL] [Abstract][Full Text] [Related]
30. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease. Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924 [TBL] [Abstract][Full Text] [Related]
31. Multi-modal neuroprotection of Talukder MEK; Akhter S; Ahammad F; Aktar A; Islam MS; Laboni AA; Afroze M; Khan M; Uddin MJ; Rahman MM Heliyon; 2024 Sep; 10(17):e37178. PubMed ID: 39286063 [No Abstract] [Full Text] [Related]
32. Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery. Jiang XY; Chen TK; Zhou JT; He SY; Yang HY; Chen Y; Qu W; Feng F; Sun HP ACS Med Chem Lett; 2018 Mar; 9(3):171-176. PubMed ID: 29541355 [TBL] [Abstract][Full Text] [Related]
33. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806 [TBL] [Abstract][Full Text] [Related]
34. Wu Y; Su X; Lu J; Wu M; Yang SY; Mai Y; Deng W; Xue Y Front Pharmacol; 2022; 13():905708. PubMed ID: 35899116 [TBL] [Abstract][Full Text] [Related]
35. Discovery of thiazolidin-4-one analogue as selective GSK-3β inhibitor through structure based virtual screening. Choudhary BS; Sukanya ; Mehta P; Bach S; Ruchaud S; Robert T; Josselin B; Filipek S; Malik R Bioorg Med Chem Lett; 2021 Nov; 52():128375. PubMed ID: 34560262 [TBL] [Abstract][Full Text] [Related]
36. Molecular docking and dynamics simulations revealed the potential inhibitory activity of honey-iQfood ingredients against GSK-3β and CDK5 protein targets for brain health. Zakaria NH; Mohamed Tap F; Aljohani GF; Abdul Majid FA J Biomol Struct Dyn; 2024 Jan; ():1-20. PubMed ID: 38165434 [TBL] [Abstract][Full Text] [Related]
37. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease. Kumar A; Srivastava G; Sharma A Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235 [TBL] [Abstract][Full Text] [Related]
38. High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches. Shukla R; Singh TR J Genet Eng Biotechnol; 2021 May; 19(1):61. PubMed ID: 33945025 [TBL] [Abstract][Full Text] [Related]
39. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis. Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130 [TBL] [Abstract][Full Text] [Related]
40. Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease. Shri SR; Manandhar S; Nayak Y; Pai KSR Adv Pharm Bull; 2023 Nov; 13(4):688-700. PubMed ID: 38022801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]